Similar articles

• Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

  Schuchter LM. Schuchter LM. J Clin Oncol. 2004 Jan 1;22(1):7-10. doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665612 No abstract available.
• Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.

  Lens M. Lens M. Dermatol Ther. 2006 Jan-Feb;19(1):9-18. doi: 10.1111/j.1529-8019.2005.00051.x. Dermatol Ther. 2006. PMID: 16405565 Review.
• Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.

  Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial.
• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

  Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.
• Malignant melanoma: non-metastatic.

  Crosby D, Crosby T, Mason M. Crosby D, et al. Clin Evid. 2002 Jun;(7):1519-29. Clin Evid. 2002. Update in: Clin Evid. 2003 Jun;(9):1842-53. PMID: 12230768 Updated. Review. No abstract available.